Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
Stock Information for Bellerophon Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.